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Abstract
Objectives To assess how often harm is quantified in randomised trials
of cancer screening.
Design Two authors independently extracted data on harms from
randomised cancer screening trials. Binary outcomes were described
as proportions and continuous outcomes with medians and interquartile
ranges.
Data sources For cancer screening previously assessed in a Cochrane
review, we identified trials from their reference lists and updated the
search in CENTRAL. For cancer screening not assessed in a Cochrane
review, we searched CENTRAL, Medline, and Embase.
Eligibility criteria for selecting studies Randomised trials that
assessed the efficacy of cancer screening for reducing incidence of
cancer, cancer specific mortality, and/or all cause mortality.
Data extraction Two reviewers independently assessed articles for
eligibility. Two reviewers, who were blinded to the identity of the study’s
authors, assessed whether absolute numbers or incidence rates of
outcomes related to harm were provided separately for the screening
and control groups. The outcomes were false positive findings,
overdiagnosis, negative psychosocial consequences, somatic
complications, invasive follow-up procedures, all cause mortality, and
withdrawals because of adverse events.
Results Out of 4590 articles assessed, 198 (57 trials, 10 screening
technologies) matched the inclusion criteria. False positive findings were
quantified in two of 57 trials (4%, 95% confidence interval 0% to 12%),
overdiagnosis in four (7%, 2% to 18%), negative psychosocial
consequences in five (9%, 3% to 20%), somatic complications in 11
(19%, 10% to 32%), use of invasive follow-up procedures in 27 (47%,
34% to 61%), all cause mortality in 34 (60%, 46% to 72%), and
withdrawals because of adverse effects in one trial (2%, 0% to 11%).
The median percentage of space in the results section that reported
harms was 12% (interquartile range 2-19%).
Conclusions Cancer screening trials seldom quantify the harms of
screening. Of the 57 cancer screening trials examined, the most
important harms of screening—overdiagnosis and false positive
findings—were quantified in only 7% and 4%, respectively.
Introduction
Cancer screening can lead to harm as well as benefit.1-3 Harm
related to screening can be somatic or psychosocial.4-13 Harms
result from the screening test itself, from investigations because
of false positive findings, and from overdiagnosis with
subsequent overtreatment.3 5 12 13 Given the potential for serious
harms in healthy individuals, screening should be offered only
when the benefits are firmly documented and considered to
outweigh the harms, which should be equally well quantified.
The determination of benefit from screening requires assessment
in randomised clinical trials, which are also capable of providing
high quality evidence on harms.14 15 In general, however, harms
are poorly reported in randomised trials,16-31 and there is some
evidence that reporting of harms is worse in
non-pharmacological trials than in trials assessing drugs.22-24
At least three additional arguments support the importance of
reporting harms in randomised trials of cancer screening. Firstly,
screening is offered to healthy individuals and is an intervention
initiated by the healthcare system, not at the request from a
patient to solve a health problem. Secondly, interventions for
which the benefits are modest or uncertain merit detailed
consideration of harms,32 and systematic reviews of randomised
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trials of screening have shown either modest33-35 or no36
reductions in cancer specific mortality. Thirdly, a benefit for
some will come at the expense of harm to others.37-39
Theminimum evidence required to assess the harms of screening
includes the frequencies of false positive findings, overdiagnosis,
and complications of diagnostic investigations and treatment.13
In addition, withdrawals because of harms19 and the use of
invasive follow-up procedures can be considered as proxy
measures of severe harms. We hypothesised that cancer
screening trials would not consistently or sufficiently quantify
the expected associated harms.
Methods
Eligibility criteria
We included trials that evaluated breast cancer screening with
mammography, self examination, or clinical examination;
colorectal cancer screening with sigmoidoscopy or colonoscopy,
faecal occult blood testing, or virtual colonoscopy; liver cancer
screening with ultrasonography, α fetoprotein, or a combination;
lung cancer screening with chest radiography or low dose spiral
computed tomography of chest; ovarian cancer screening with
ultrasonography, serological markers, or a combination; oral
cancer screening with visual inspection; prostate cancer
screening with prostate specific antigen, digital rectal
examination, or a combination; and testicular cancer screening
with self examination or clinical examination.
Publications reporting randomised trials were eligible if the trial
compared a group of participants undergoing a cancer screening
intervention with either no screening or an alternative screening
intervention. Participants could be part of the general population
or of a high risk population, such as heavy smokers. Trials had
to assess the efficacy of cancer screening, defined as a reduction
in the incidence of cancer, cancer specific mortality, or all cause
mortality. Trials were included regardless of risk of bias.
Individual articles were eligible if they provided data for both
the screening and control groups, and if they did not pool data
from randomised trials and observational studies. Finally, to be
eligible, articles must have provided data for all participants, a
random sample of all participants, or all participants enrolled
in a single centre of a multicentre trial.
Search strategy for the identification of
articles
We extracted the references to trials from Cochrane Systematic
Reviews when these were available and performed an updated
search in the Cochrane Central Register of Controlled Trials
using the search terms described in each Cochrane review to
find articles published since the review (appendix 1).
When no Cochrane Systematic Reviewwas available, we sought
clinical trial reports in the Cochrane Central Register of
Controlled Trials. Our search strategies used a combination of
controlled vocabulary (MeSH terms) and free text terms. They
had three dimensions: terms related to cancer, terms related to
the screening technology, and the term “screening” and its
synonyms (appendix 1). We planned not to have language
restriction, but because of lack of resources we were unable to
translate 12 articles identified for assessment of eligibility (six
in Mandarin and six in Russian). Our last search was in May
2012.
It subsequently became clear that our search strategy missed
some potentially relevant articles. We amended the protocol
and designed new searches including either the name of trials
known to us or the name of the principal investigators of the
trials. These new searches were performed inMedline (1946-14
Aug 2012), Medline In-process and other non-indexed citations
(to 14 Aug 2012), and Embase (1974-14 Aug 2012) (appendix
1).
We did not contact study authors nor did we perform searches
of grey literature, such as doctoral theses or conference
proceedings, as this would not reflect the information that is
readily available in the literature.
Data collection and analysis
Selection of studies
BH and DSR independently scanned the titles and abstracts
from reference lists of Cochrane Systematic Reviews and from
the electronic searches.When the title or abstract did not provide
sufficient data to rule out eligibility, the full text was obtained.
Disagreements were solved through consensus.
Data extraction and management
All articles were collected in a digital file format (pdf). Two
weeks before data extraction, BH concealed information about
authors, affiliations, date of publication, journal, and references
with the stamp function in Adobe Acrobat 9 Pro (version 9.5.2).
The pdf files were encrypted with a password, which restricted
changes in the file security settings. BH andMFT independently
extracted the data using standardised forms and blinded to each
other’s results. Both authors extracted the data from the
encrypted pdf files that concealed author identification, year of
publication, and the name of the journal, but not trial
identification. Disagreements were solved through consensus.
When results from a single trial were reported in multiple
publications, data were collected in separate forms for each
publication, but our unit of analysis was at trial level. If a single
publication provided data from two or more trials, information
for each trial was collected in separate forms.
Harm data
We included seven types of harms related to cancer screening:
overdiagnosis, false positive findings, somatic complications
caused by screening or follow-up procedures, negative
psychosocial consequences caused by screening test or follow-up
procedures, the additional number of participants subjected to
invasive procedures, all cause mortality (which might increase
if harms include, for example, invasive follow-up procedures
or substantial overdiagnosis and overtreatment), andwithdrawals
because of adverse events. For the qualitative assessment of
harms, we required that two criteria were met before considering
that an outcome had been reported: the absolute numbers or
incidence rates had to be provided and the outcome must have
been explicitly mentioned. We accepted the trial authors’
definition of the outcome and did not assess whether that
definition was appropriate. For example, in sigmoidoscopy trials
we considered that false positives had been reported if false
positives were mentioned, regardless of they were defined as a
screening test with a positive result but no cancer, a screening
test with positive result but no advanced adenoma or cancer, or
a screening test with a positive result but no polyp.
We also extracted a crude quantitative measure of harm
reporting. We marked the results section of each publication
using a 1 cm2 grid. Thereafter, we measured the space devoted
to the results section and the space devoted to reporting any of
the harms mentioned above. The quantitative measure of harm
reporting was the percentage of space devoted to harms out of
the total space in the results section. Similar quantitative
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measures have been used in previous reviews of reporting of
harm in randomised trials.19 23 24 30
Other publication parameters
We extracted information on the type of screening technology,
the year of recruitment of the first participant, whether disease
specific mortality or incidence had been quantified, target
population (general population or high risk group), geographical
location, type of control group (unscreened group or alternative
screening technology), and whether participants were
individually or cluster randomised. If publications from the
same trial mentioned different dates for the year of recruitment
of the first participant, we chose the earliest date.
Data at trial level
We pooled data from all articles from the same trial. If at least
one article from the trial did so, we considered that a trial had
quantified a specific harm. We applied the same criterion to
data on incidence of cancer and mortality. When trials were
reported in more than one article, the space devoted to the results
section was defined as the sum of the space of the results
sections in each article. Likewise, the space devoted to harms
was the sum of the space devoted to harms in each of the articles
reporting that trial.
Prespecified analyses
Analyses consisted of a descriptive assessment of included
variables. We used proportions and exact confidence intervals
for binary outcomes and medians and interquartile ranges for
continuous outcomes. In the protocol, we hypothesised that the
date of enrolment of participants could be an explanatory
variable for quantification of harm and that this could be tested
with regression models. Because of a lack of data, however,
this could not be done. All statistical analyses were performed
in R version 3.0.1.
Additional analyses
In the original protocol (appendix 2), we specified that we would
include only articles that reported data from all trial arms.While
BH and DSRwere assessing the articles for eligibility, we noted
that several articles contained relevant information on harms
only for the screened participants. Hence, BH reassessed all
articles related to the included trials and identified those that
reported data on harms only in the intervention group. These
articles were included in an unplanned subsidiary analysis to
test the robustness of the findings of the main analysis. As 12
articles were not translated, we preformed another unplanned
sensitivity analysis assuming that these articles had quantified
harms.
We tabulated harm quantification according to the screening
technology, geographical location, and type of control group
(unscreened group or alternative screening technology). Given
the small number of trials, we did not perform stratified
statistical analysis. In some trials screening led to a reduced
incidence of cancer (thus, if overdiagnosis existed it would be
impossible to detect), and in other trials the study design might
have been inappropriate to assess it (short follow-up or use of
another screening intervention as a control group), so we
performed an analysis that excluded both these groups of trials
from the denominators.
The protocol for this literature review and its amendment are
available in appendix 2.
Results
Out of 4590 titles identified, we found 63 trials that aimed to
assess the effect of cancer screening on cancer specific or all
cause mortality, or both. Of these, only 57 had published results
in at least one article that matched our eligibility criteria (figure⇓
and appendix 3). Of the six remaining trials, one trial was not
completed because of low compliance, one trial had not started
enrolling participants, and four trials are not yet completed.
These four trials have reported results for the screened group
but not for the control group. The 57 trials assessed 10 different
screening interventions and enrolled 3 419 036 participants. We
found no trials on testicular cancer screening or colorectal cancer
screening with virtual colonoscopy.
Some of the 57 trials were reported in several articles. We found
198 articles that included data on both the screened and the
control groups and used these in our main analyses. We also
found 44 articles that reported data for the screened groups but
not for the control groups. Our analyses were replicated in the
combined 242 articles to assess whether harms had been
quantified in at least the screened groups.
Table 1 shows the proportion of trials that quantified each
individual outcome in at least one of the eligible articles
describing that trial⇓ (the individual assessment of the trials and
respective characteristics are available from the authors).
Overall, cancer specific mortality and cancer specific incidence
were quantified more often than harm related outcomes. While
the former two were quantified in more than 80% of the trials,
false positive findings were quantified for only two trials (4%,
95% confidence interval 0% to 12%), and overdiagnosis was
quantified in four trials (7%, 2% to 18%). Only one trial (2%,
0% to 11%) quantified the number of withdrawals because of
adverse effects. The median percentage of space in the results
section devoted to harms data was 12% (interquartile range
2-19%). Table 2 shows quantification of harm stratified by type
of screening.⇓ Quantification of harm stratified by geographical
location of the trial and type of control group is shown in tables
S1 and S2 in appendix 4.
We performed several sensitivity analyses with less strict
criteria. When we also considered the 44 articles that reported
data from only the screened groups, the proportion of trials that
quantified some of the harms increased (table 1⇓). For example,
false positive findings were now quantified in 32% (95%
confidence interval 20% to 45%) of trials, while overdiagnosis
remained quantified in only 7% of trials. The results of the
sensitivity analyses—which assumed the non-translated articles
had quantified all the outcomes—were similar to those of the
main analyses (table S3 in appendix 4). We also restricted the
analysis of overdiagnosis to the trials which, after extended
follow-up, found a higher incidence of cancer in screened
participants than in the unscreened control group. In this subset,
overdiagnosis was quantified in two out of 12 trials (17%, 2%
to 48%).
Discussion
Summary of main results
The most important harms of screening—overdiagnosis and
false positive findings—were quantified in only a minority of
trials. Out of 57 cancer screening trials, 7% quantified
overdiagnosis40-43 and 4% quantified false positive results.44 45
Only one trial reported the number of withdrawals because of
harmful events (2%),46 and the median amount of space devoted
to reporting of harms in the results section of the trial reports
was 12%. Consequently, cancer screening trials rarely report
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what is considered the minimum amount of evidence required
to quantify the harms of screening. In contrast, the effect of
cancer screening on cancer specific mortality was reported in
89% of trials. It is therefore often difficult or impossible to
weigh benefits against harms in cancer screening.
Interpretation of the results
We found few trials that met our criteria for minimal harm
reporting, which suggests poor reporting of harms. An
alternative explanation would be that our assessment criteria
focus on irrelevant outcomes or that they do not capture the
important aspects of harm reporting. Their relevance, however,
is supported in several concept papers and editorials about the
harms of screening.4-13 The exception is withdrawals, which is
an unusual concept in screening literature and was taken from
previous reviews of harm reporting.16 19 We included this
outcome because it reflects the ultimate decision of the
participant, the physician, or both, to discontinue an
intervention.16 The importance of withdrawals, however, is
controversial,32 and trialists might have considered it irrelevant.
When the decision to withdraw is made by a clinician, it is
possible to recognise this from the participant’s case report
form; but when the decision is taken by the participant it might
be difficult to distinguish it from other causes of loss to
follow-up. Additionally, in some trials there was no direct
contact with the control group and their information was
collected from registries. These participants could not withdraw
as they were unaware that they were part of a trial. In these trials
it would be inappropriate to require withdrawal data from the
controls. In summary, there are arguments against the relevance
of withdrawals as a surrogate of harm; however, even when we
excluded this outcome, the general pattern of poor reporting of
harm persisted.
Three aspects of the criteria used to appraise the harm outcomes
could be discussed. The first is whether these outcomes can be
assessed for all trials. It is possible to argue that overdiagnosis
cannot be assessed in all trials as this ideally requires a persistent
increase in incidence after a long follow-up.41 47 We chose to
present overdiagnosis by including all 57 trials in the
denominator as it had been specified in our review protocol.
For completeness, we also restricted the analysis to trials with
long term follow-up, an increased incidence of cancer in the
screened group, and an unscreened control group. Although the
proportion of trials reporting overdiagnosis is higher in this
subset (17% compared with 7% in the main analysis), it is still
unacceptably low and makes no change to our conclusion. We
found no reason to exclude trials from the denominators of the
other analyses.
The second point is whether it is relevant to collect data from
the unscreened arms for all harm outcomes. Reporting harm
outcomes for the intervention and control groups is a central
recommendation in the guidelines for reporting randomised
trials,48 49 and we therefore assessed whether each screening
harm was reported in both groups of the trials. Symptoms and
incidental findings in unscreened participants can lead to
invasive procedures, adverse psychosocial consequences,
complications of diagnosis and treatment, and mortality from
other causes. Hence, these four outcomes should be reported
for the control groups to make it possible to assess the level of
any surplus harm in the screened group. In contrast, it can be
argued that it is necessary to undergo a screening test to
experience a false positive result. If we accept this premise,
participants in unscreened control groups cannot experience
false positive findings and it would be adequate to report false
positives only for the screened group when the comparator is
no screening. This would mean that 18 trials (32%) would have
reported false positive findings adequately, instead of the two
(4%) that report them for both arms. Even if we allow for a less
strict criterion, the vast majority of trials do not provide data
on false positive findings. It is also possible to argue that it is
not meaningful to report overdiagnosis for the screened and the
unscreened groups because it can be quantified only indirectly
(that is, comparing the incidence between groups). We
considered, however, that overdiagnosis was reported when
incidence data had been provided for both arms and the term
“overdiagnosis” or equivalent had been used.
Thirdly, we could have included data presented outside of the
results section. Some trials presented data on harm in the
discussion section but not in the results section: five trials
presented numbers for overdiagnosis,50-54 three trials presented
the number of false positive results in the screened group,55-57
and one presented the number of invasive procedures in the
screened group.57 In the case of overdiagnosis, the trials
presented the difference in incidence of cancer in the results
section and interpreted this as overdiagnosis in the discussion
section. Addition of these to the numerator would mean that of
57 trials, nine (16%, 95% confidence interval 7% to 28%)
reported overdiagnosis. When we considered the smaller subset
of 12 trials with long term follow-up, increased incidence of
cancer in the screened group, and an unscreened control group,
overdiagnosis was reported in four trials (33%, 10% to 65%).
Thus, in the most optimistic scenario only a third of the trials
report the most serious harm of screening.
Strengths and weaknesses
We identified trial articles from either Cochrane Reviews or
electronic searches in three different databases. It is therefore
unlikely that we missed any important article for the trials
included in this review. Our searches also identified trials of
screening interventions that we were not aware of before this
study (for example, cervical cancer screening with visual
inspection or human papillomavirus typing). We have not
included these in this review, which is therefore not fully
comprehensive.
We tried to avoid underestimation of quantification of harm in
four ways. Firstly, we assessed only whether any quantification
of harms was present, not whether the harms were adequately
reported or correctly defined. Secondly, we considered that
harms had been reported even when the quality of the data on
harms was lower than that for benefits (that is, when harms data
were reported for only a subset of the included participants).
Thirdly, when data on harms were provided in a table or a figure,
we included the entire table or figure area in the numerator of
our estimate of space devoted to harms. Data on harms often
accounted for a small number of lines in a table. Finally, and
unlike previous surveys of harm reporting,16-25 27 we extracted
data from multiple articles reporting on a single trial.
Most of the concept papers and editorials about harms of
screening were published within the past decade.4 7-12 Also, the
data monitoring committee of the PLCO trial has recently
recommended early stopping of the prostate cancer screening
part because of concerns about harms.58 This suggests more
concern about screening harms in recent years. Because of the
small number of trials, however, we could not assess whether
harm reporting has improved in recent years, as originally
planned in the review protocol.
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Strengths andweaknesses in relation to other
studies
Several authors have stated that adequate evidence on the harms
of cancer screening is lacking.5 12 13 59 We identified only one
previous study that attempted to quantify the problem. This was
a review of research articles about mammography screening
including study designs other than randomised trials. Thirty
eight per cent of the included articles did not report any harms;
23% mentioned harms but presented them as unimportant; and
39% acknowledged the existence of harms.60Our results extend
this finding to other types of cancer screening.
Several literature reviews have assessed harms reported in
randomised trials of other types of medical interventions.16-31 In
these reviews, the proportion of trials reporting absolute numbers
for various harms ranged from 41% to 88%,19 23 24 27 29
withdrawals because of harms in 25-94%,19 21 23 24 26 27 30 and the
median space devoted to harms in the results section ranged
from 0% to 14%.19 20 23 30Although cancer screening trials assess
a preventive activity targeted at healthy individuals, our results
show that reporting of harm is no better than what was found
in reviews of therapeutic interventions.
Meaning of the study
The trials we reviewed included large numbers of participants,
followed them for long periods of time, requiredmany resources,
and provided valuable information about the impact of screening
on cancer specific mortality. However, we found that the harms
were poorly reported. Healthcare decision makers, healthcare
practitioners, and, ultimately, patients therefore cannot make
informed choices about cancer screening. This is problematic
asmany cancer screening programmes have important associated
harms.
While we acknowledge that collecting data on harms will
complicate cancer screening trials, this is not a sound argument
against the strong ethical obligation to collect such data. If
trialists do not report certain outcomes because they consider
that the harms will be either rare or irrelevant when compared
with the potential decrease in mortality, such information will
not be available for people who judge these outcomes
differently. We think that future screening trials should collect
and report the expected harms of screening (false positives,
overdiagnosis and overtreatment, psychosocial consequences,
somatic complications, and all cause mortality). Adequate
reporting of harm requires data from the control group as these
provide a reference level and help to interpret harms data from
the screened group.
Implications for future research
The CONSORT statement,48 49which aims to improve reporting
of clinical trials, has an extension specifically devoted to
reporting of harm.16 Although most of the examples in this
extension come from pharmacological trials, the extension is
also applicable to screening trials. There are some topics,
however, where direct application of the CONSORT statement
to cancer screening trials seems difficult. How can withdrawals
because of harmful events be distinguished from other sources
of loss to follow-up in screening trials? Are there specific harms
in cancer screening where data from the intervention group is
enough? Can scales be used to grade screening harms for
severity? A discussion of these questions could help to
standardise harm reporting in randomised trials of cancer
screening and will hopefully lead to more complete evidence
that allows informed decisions.
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What is known about this topic
Cancer screening programmes require detailed consideration of harms as they target healthy people
Harms from screening include overdiagnosis and overtreatment, false positive findings, additional invasive procedures, negative
psychosocial consequences, and somatic complications
It is unknown whether trials that assess cancer screening routinely quantify harms
What this study adds
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Tables
Table 1| Number of trials of cancer screening that quantified cancer mortality, incidence, and harms
Trials that quantify data at least in screened group†
Trials that quantify data for screened and control
groups*
Percentage of trials (95%CI)Absolute numberPercentage of trials (95% CI)Absolute number
—57—57Total No of trials
General outcomes:
82 (70 to 91)4782 (70 to 91)47Cancer specific mortality
93 (83 to 98)5389 (78 to 96)51Cancer specific incidence
Harm outcomes:
5 (1 to 15)32 (0 to 9)1Withdrawals because of adverse
events
7 (2 to 17)47 (2 to 17)4Numerical estimate for overdiagnosis
32 (20 to 45)184 (0 to 12)2Numerical estimate for false positive
findings
14 (6 to 26)89 (3 to 19)5Numerical estimate for negative
psychosocial consequences
35 (23 to 49)2019 (10 to 32)11Numerical estimate for somatic
complications
81 (68 to 90)4647 (34 to 61)27Numerical estimate for invasive
procedures
60 (46 to 72)3460 (46 to 72)34All cause mortality
*198 articles provided data for both intervention and control groups.
†242 articles provided data for at least intervention group (198 for both groups and 44 for screened group alone).
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Table 2| Number of trials and number of articles for different screening technologies. Figures are numbers of trials that provided data for









53158376145Total No of trials




















17 (1-18)14(7-20)326 (25-30)15 (13-19)14 (7-17)4 (1-16)10 (2-18)7 (2-13)5 (0-7)Median (IQR) space
devoted to harm (%)
BSE/BCE=breast self examination/breast clinical examination; Mam=mammography; FOBT=faecal occult blood test; Sigm=sigmoidoscopy or colonoscopy;
US/AF=ultrasonography/α fetoprotein; CXR=chest radiography; CCT=chest computed tomography; VI=visual inspection; US/CA125=ultrasonography/cancer
antigen 125; PSA=prostate specific antigen; DRE=digital rectal examination; IQR=interquartile range.
*Data for each trial could be provided in one or more publications. References to included articles are presented in appendix 3.
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Figure
Flow diagram of articles screened, assessed for eligibility, and included in analysis
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